Display options
Cite
Rebollo J, Geliebter J, Reyes N. ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells. Int J Biomed Sci. 2017;13(1):35-42
Rebollo, J., Geliebter, J., & Reyes, N. (2017). ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells. International journal of biomedical science : IJBS, 13(1), 35-42.
Rebollo, Juan, et al. "ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells." International journal of biomedical science : IJBS vol. 13,1 (2017): 35-42.
Rebollo J, Geliebter J, Reyes N. ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells. Int J Biomed Sci. 2017 Mar;13(1):35-42. PMID: 28533735; PMCID: PMC5422643.
Copy Download .nbib Format: NLM
Share it on

Int J Biomed Sci. 2017 Mar;13(1):35-42.

ESM-1 siRNA Knockdown Decreased Migration and Expression of CXCL3 in Prostate Cancer Cells.

International journal of biomedical science : IJBS

Juan Rebollo, Jan Geliebter, Niradiz Reyes

Affiliations

  1. Research group of Genetics and Molecular Biology. School of Medicine. University of Cartagena. Colombia.
  2. Graduate School of Basic Medical Sciences. New York Medical College. Valhalla, NY, United States.

PMID: 28533735 PMCID: PMC5422643

Abstract

Endothelial cell-specific molecule-1 (ESM-1), also known as endocan, is a soluble proteoglycan expressed by the vascular endothelium, which also circulates in the bloodstream. Inflammatory cytokines and proangiogenic growth factors increase its expression, and increased serum levels have been reported in several cancer types and immunocompetent patients with sepsis. The aim of this study was to analyze the expression profile of CXC-chemokines and the effects of ESM-1 gene knockdown in proliferation, migration and CXC-chemokine expression in highly metastatic human prostate PC-3 cells. Expression profiles of CXC-chemokines were analyzed in metastatic PC-3 and non-tumorigenic PWR-1E cells. siRNA-mediated knockdown of ESM-1 was performed into PC-3 cells, which were subsequently tested for cell migration and proliferation. Effect of siRNA transfection on CXC-chemokine expression was further quantified at the transcript and protein level. RT-qPCR analysis and sandwich ELISA assay revealed higher levels of ESM-1 and several CXC-chemokines in metastatic PC-3 cells compared to non-tumorigenic PWR-1E. Transfection of PC-3 cells with ESM-1-siRNA decreased cell migration with no effect on proliferation, and it was accompanied by decrease in the transcript and protein levels of the angiogenic chemokine CXCL3. We report here for the first time the ESM-1 targeting in PC-3 cells, which resulted in decreased migration, which may be related, at least in part, to decreased expression of the angiogenic CXCL3 chemokine, whose expression was found to be reduced in ESM-1-siRNA transfected cells. Additional studies are required to ascertain the biological role of ESM-1 in prostate cancer cells and the link with the expression of CXCL3.

Keywords: ESM-1 knockdown; chemokines; endocan; migration; prostate cancer; proteoglycans

References

  1. Hematology. 2011 Nov;16(6):351-6 - PubMed
  2. Int J Biol Markers. 2016 May 28;31(2):e153-62 - PubMed
  3. Microvasc Res. 2002 Mar;63(2):159-71 - PubMed
  4. Biotechniques. 2009 Apr;46(4):265-74 - PubMed
  5. BMC Bioinformatics. 2012 Jun 18;13:134 - PubMed
  6. Semin Cancer Biol. 2004 Jun;14(3):195-200 - PubMed
  7. Exp Cell Res. 2007 Apr 15;313(7):1285-94 - PubMed
  8. Int Urol Nephrol. 2016 May;48(5):701-9 - PubMed
  9. Biomedica. 2007 Jun;27(2):190-203 - PubMed
  10. Thromb Haemost. 2007 May;97(5):755-62 - PubMed
  11. J Cereb Blood Flow Metab. 2009 Sep;29(9):1503-16 - PubMed
  12. J Biol Chem. 1995 Nov 10;270(45):27348-57 - PubMed
  13. Prostate Cancer Prostatic Dis. 2016 Dec;19(4):395-397 - PubMed
  14. Oncol Rep. 2012 Nov;28(5):1701-8 - PubMed
  15. Crit Rev Oncol Hematol. 2002 Oct;44(1):17-27 - PubMed
  16. Int J Mol Med. 2013 Oct;32(4):763-7 - PubMed
  17. J Neurosci. 2012 Oct 31;32(44):15547-64 - PubMed
  18. J Vasc Res. 2000 Sep-Oct;37(5):417-25 - PubMed
  19. J Leukoc Biol. 2000 Jul;68(1):1-8 - PubMed
  20. Life Sci. 2006 Mar 13;78(16):1784-93 - PubMed
  21. J Cancer. 2014 Mar 04;5(3):221-30 - PubMed
  22. Clin Lab. 2014;60(3):505-10 - PubMed
  23. Nat Protoc. 2007;2(2):329-33 - PubMed
  24. J Neuropathol Exp Neurol. 2009 Jun;68(6):633-41 - PubMed
  25. Adv Cancer Res. 2010;106:91-111 - PubMed
  26. Amino Acids. 2011 Mar;40(3):1003-13 - PubMed
  27. Cancer Res. 2002 Feb 1;62(3):665-8 - PubMed
  28. Can J Gastroenterol Hepatol. 2015 Nov-Dec;29(8):427-30 - PubMed
  29. Cell Signal. 2012 Oct;24(10):1940-9 - PubMed
  30. Pharmacol Rev. 2000 Mar;52(1):145-76 - PubMed
  31. Cancer Commun. 1991 Jul;3(7):207-12 - PubMed
  32. CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30 - PubMed
  33. Biochim Biophys Acta. 2006 Jan;1765(1):25-37 - PubMed
  34. Shock. 1995 Sep;4(3):155-60 - PubMed
  35. Vasc Health Risk Manag. 2006;2(3):213-9 - PubMed
  36. J Vasc Res. 2002 Mar-Apr;39(2):148-59 - PubMed

Publication Types